Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Ryozo Nagai is active.

Publication


Featured researches published by Ryozo Nagai.


Arteriosclerosis, Thrombosis, and Vascular Biology | 2001

Troglitazone Inhibits Atherosclerosis in Apolipoprotein E–Knockout Mice Pleiotropic Effects on CD36 Expression and HDL

Zhong Chen; Shun Ishibashi; Stéphane Perrey; Jun-ichi Osuga; Takanari Gotoda; Tetsuya Kitamine; Yoshiaki Tamura; Hiroaki Okazaki; Naoya Yahagi; Yoko Iizuka; Futoshi Shionoiri; Ken Ohashi; Kenji Harada; Hitoshi Shimano; Ryozo Nagai; Nobuhiro Yamada

Abstract —Atherosclerotic coronary heart disease is a common complication of the insulin resistance syndrome that can occur with or without diabetes mellitus. Thiazolidinediones (TZDs), which are insulin-sensitizing antidiabetic agents, can modulate the development of atherosclerosis not only by changing the systemic metabolic conditions associated with insulin resistance but also by exerting direct effects on vascular wall cells that express peroxisome proliferator–activated receptor-&ggr; (PPAR-&ggr;), a nuclear receptor for TZDs. Here we show that troglitazone, a TZD, significantly inhibited fatty streak lesion formation in apolipoprotein E–knockout mice fed a high-fat diet (en face aortic surface lesion areas were 6.9±2.5% vs 12.7±4.7%, P <0.05; cross-sectional lesion areas were 191 974±102 911 &mgr;m2 vs 351 738±175 597 &mgr;m2, P <0.05; n=10). Troglitazone attenuated hyperinsulinemic hyperglycemia and increased high density lipoprotein cholesterol levels. In the aorta, troglitazone markedly increased the mRNA levels of CD36, a scavenger receptor for oxidized low density lipoprotein, presumably by upregulating its expression, at least in part, in the macrophage foam cells. These results indicate that troglitazone potently inhibits fatty streak lesion formation by modulating both metabolic extracellular environments and arterial wall cell functions.


Journal of Biological Chemistry | 2000

Sterol Regulatory Element-binding Protein-1 Is Regulated by Glucose at the Transcriptional Level

Alyssa H. Hasty; Hitoshi Shimano; Naoya Yahagi; Michiyo Amemiya-Kudo; Stéphane Perrey; Tomohiro Yoshikawa; Jun-ichi Osuga; Hiroaki Okazaki; Yoshiaki Tamura; Yoko Iizuka; Futoshi Shionoiri; Ken Ohashi; Kenji Harada; Takanari Gotoda; Ryozo Nagai; Shun Ishibashi; Nobuhiro Yamada

In vivo studies suggest that sterol regulatory element-binding protein (SREBP)-1 plays a key role in the up-regulation of lipogenic genes in the livers of animals that have consumed excess amounts of carbohydrates. In light of this, we sought to use an established mouse hepatocyte cell line, H2-35, to further define the mechanism by which glucose regulates nuclear SREBP-1 levels. First, we show that these cells transcribe high levels of SREBP-1c that are increased 4-fold upon differentiation from a prehepatocyte to a hepatocyte phenotype, making them an ideal cell culture model for the study of SREBP-1c induction. Second, we demonstrate that the presence of precursor and mature forms of SREBP-1 protein are positively regulated by medium glucose concentrations ranging from 5.5 to 25 mm and are also regulated by insulin, with the amount of insulin in the fetal bovine serum being sufficient for maximal stimulation of SREBP-1 expression. Third, we show that the increase in SREBP-1 protein is due to an increase in SREBP-1 mRNA. Reporter gene analysis of the SREBP-1c promoter demonstrated a glucose-dependent induction of transcription. In contrast, expression of a fixed amount of the precursor form of SREBP-1c protein showed that glucose does not influence its cleavage. Fourth, we demonstrate that the glucose induction of SREBP could not be reproduced by fructose, xylose, or galactose nor by glucose analogs 2-deoxy glucose and 3-O-methyl glucopyranose. These data provide strong evidence for the induction of SREBP-1c mRNA by glucose leading to increased mature protein in the nucleus, thus providing a potential mechanism for the up-regulation of lipogenic genes by glucosein vivo.


Journal of Biological Chemistry | 2002

Elimination of Cholesterol Ester from Macrophage Foam Cells by Adenovirus-mediated Gene Transfer of Hormone-sensitive Lipase

Hiroaki Okazaki; Jun-ichi Osuga; Kazuhisa Tsukamoto; Naoyuki Isoo; Tetsuya Kitamine; Yoshiaki Tamura; Sachiko Tomita; Motohiro Sekiya; Naoya Yahagi; Yoko Iizuka; Ken Ohashi; Kenji Harada; Takanari Gotoda; Hitoshi Shimano; Satoshi Kimura; Ryozo Nagai; Nobuhiro Yamada; Shun Ishibashi

Cholesterol ester (CE)-laden foam cells are a hallmark of atherosclerosis. To determine whether stimulation of the hydrolysis of cytosolic CE can be used as a novel therapeutic modality of atherosclerosis, we overexpressed hormone-sensitive lipase (HSL) in THP-1 macrophage-like cells by adenovirus-mediated gene delivery, and we examined its effects on the cellular cholesterol trafficking. We show here that the overexpression of HSL robustly increased neutral CE hydrolase activity and completely eliminated CE in the cells that had been preloaded with CE by incubation with acetylated low density lipoprotein. In these cells, cholesterol efflux was stimulated in the absence or presence of high density lipoproteins, which might be at least partially explained by the increase in the expression of ABCA1. Importantly, these effects were achieved without the addition of acyl-CoA:cholesterol acyltransferase inhibitor, cAMP, or even high density lipoproteins. Furthermore, the uptake and degradation of acetylated low density lipoprotein was significantly reduced probably by decreased expression of scavenger receptor A and CD36. Notably, the cells with stimulated CE hydrolysis did not exhibit either buildup of free cholesterol or cytotoxicity. In conclusion, increased hydrolysis of CE by the overexpression of HSL leads to complete elimination of CE from THP-1 foam cells not only by increasing efflux but also by decreasing influx of cholesterol.


Journal of Biological Chemistry | 2002

Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lepob/Lepob mice

Naoya Yahagi; Hitoshi Shimano; Alyssa H. Hasty; Takashi Matsuzaka; Tomohiro Ide; Tomohiro Yoshikawa; Michiyo Amemiya-Kudo; Sachiko Tomita; Hiroaki Okazaki; Yoshiaki Tamura; Yoko Iizuka; Ken Ohashi; Jun-ichi Osuga; Kenji Harada; Takanari Gotoda; Ryozo Nagai; Shun Ishibashi; Nobuhiro Yamada


Journal of Biological Chemistry | 2001

Severe Hypercholesterolemia, Hypertriglyceridemia, and Atherosclerosis in Mice Lacking Both Leptin and the Low Density Lipoprotein Receptor

Alyssa H. Hasty; Hitoshi Shimano; Jun-ichi Osuga; Ichiji Namatame; Akimitsu Takahashi; Naoya Yahagi; Stéphane Perrey; Yoko Iizuka; Yoshiaki Tamura; Michiyo Amemiya-Kudo; Tomohiro Yoshikawa; Hiroaki Okazaki; Ken Ohashi; Kenji Harada; Takashi Matsuzaka; Hirohito Sone; Takanari Gotoda; Ryozo Nagai; Shun Ishibashi; Nobuhiro Yamada


Journal of Biological Chemistry | 2001

Asialoglycoprotein Receptor Deficiency in Mice Lacking the Major Receptor Subunit ITS OBLIGATE REQUIREMENT FOR THE STABLE EXPRESSION OF OLIGOMERIC RECEPTOR

Ryu-ichi Tozawa; Shun Ishibashi; Jun-ichi Osuga; Kazuo Yamamoto; Hiroaki Yagyu; Ken Ohashi; Yoshiaki Tamura; Naoya Yahagi; Yoko Iizuka; Hiroaki Okazaki; Kenji Harada; Takanari Gotoda; Hitoshi Shimano; Satoshi Kimura; Ryozo Nagai; Nobuhiro Yamada


Journal of Biological Chemistry | 2005

High Mobility Group Protein-B1 Interacts with Sterol Regulatory Element-binding Proteins to Enhance Their DNA Binding

Yuho Najima; Naoya Yahagi; Yoshinori Takeuchi; Takashi Matsuzaka; Motohiro Sekiya; Yoshimi Nakagawa; Michiyo Amemiya-Kudo; Hiroaki Okazaki; Sachiko Okazaki; Yoshiaki Tamura; Yoko Iizuka; Ken Ohashi; Kenji Harada; Takanari Gotoda; Ryozo Nagai; Takashi Kadowaki; Shun Ishibashi; Nobuhiro Yamada; Jun-ichi Osuga; Hitoshi Shimano


Archive | 2009

Adiponectin receptor and gene encoding the same

Takashi Kadowaki; Toshimasa Yamauchi; Ryozo Nagai; Junji Kamon


Archive | 2003

Preventive/remedy for arteriosclerosis

Takashi Kadowaki; Toshimasa Yamauchi; Naoto Kubota; Yasuo Terauchi; Tetsuya Kubota; Tetsuo Noda; Ryozo Nagai; Yasushi Imai


Archive | 2009

METHOD FOR TREATING VASCULAR DISEASE

Ryozo Nagai; Takayuki Shindo; Ichiro Manabe; Koichi Shudo; Hiroyuki Kagechika

Collaboration


Dive into the Ryozo Nagai's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Yasushi Imai

Jichi Medical University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge